Whittier Trust Co. of Nevada Inc. Boosts Stake in ICON Public Limited (NASDAQ:ICLR)

Whittier Trust Co. of Nevada Inc. lifted its holdings in ICON Public Limited (NASDAQ:ICLR) by 128.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,166 shares of the medical research company’s stock after buying an additional 655 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in ICON Public were worth $245,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of ICLR. First Horizon Advisors Inc. lifted its stake in shares of ICON Public by 33.9% in the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after buying an additional 151 shares in the last quarter. Foyston Gordon & Payne Inc purchased a new position in shares of ICON Public in the third quarter worth about $11,672,000. GAMMA Investing LLC lifted its stake in shares of ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock worth $91,000 after buying an additional 169 shares in the last quarter. Steph & Co. lifted its stake in shares of ICON Public by 3.7% in the fourth quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock worth $327,000 after buying an additional 55 shares in the last quarter. Finally, Park Place Capital Corp raised its stake in ICON Public by 281.4% during the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after purchasing an additional 166 shares during the period. 95.61% of the stock is owned by hedge funds and other institutional investors.

ICON Public Stock Up 0.5 %

Shares of NASDAQ ICLR opened at $184.87 on Monday. The stock has a market cap of $14.93 billion, a P/E ratio of 19.40, a PEG ratio of 1.86 and a beta of 1.21. The business’s fifty day simple moving average is $192.76 and its 200-day simple moving average is $225.70. ICON Public Limited has a 12-month low of $174.93 and a 12-month high of $347.72. The company has a current ratio of 1.26, a quick ratio of 1.34 and a debt-to-equity ratio of 0.36.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. ICON Public had a return on equity of 11.81% and a net margin of 9.56%. The business had revenue of $2.04 billion during the quarter, compared to analysts’ expectations of $2.04 billion. As a group, equities analysts predict that ICON Public Limited will post 13.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ICLR shares. Citigroup reduced their target price on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Robert W. Baird reduced their target price on shares of ICON Public from $221.00 to $203.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. JPMorgan Chase & Co. reduced their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. William Blair reaffirmed an “outperform” rating on shares of ICON Public in a research note on Tuesday, January 14th. Finally, Truist Financial reduced their target price on shares of ICON Public from $284.00 to $262.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Five research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $272.50.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.